Pdl Biopharma (PDLI) 8.41 $PDLI
Coverage of Biotech Equities -- Research on Arena Pharma, Celgene, PDL BioPharma, and Hemispherx Biopharma
PR Newswire - Tue Apr 08, 12:20PM CDT
On Monday, April 07, 2014, the NASDAQ Composite ended at 4,079.75, down 1.16%, the Dow Jones Industrial Average finished the session 1.02% lower at 16,245.87, and the S&P 500 closed at 1,845.04, down 1.08%. The losses were broad based as nine out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index finished the day 1.06% lower at 664.68, while the same has gained 3.19% in the previous three months. Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Celgene Corp. (NASDAQ: CELG), PDL BioPharma Inc. (NASDAQ: PDLI) and Hemispherx Biopharma Inc. (NYSE MKT: HEB). Free technical research on ARNA, CELG, PDLI and HEB can be downloaded upon signing up at:
Kaleo awarded USD150m debt financing in support of EVZIO's commercial activities
M2 - Tue Apr 08, 7:07AM CDT
Pharmaceutical company Kaleo reported on Monday the execution of a USD150m debt facility with PDL BioPharma (NasdaqGS
DLI).
kaleo announces $150 million debt financing to support commercialization of EVZIO(TM)
PR Newswire - Mon Apr 07, 6:51AM CDT
Kaleo (formerly Intelliject) today announced that it has entered into a $150 million debt facility with PDL BioPharma (NASDAQ: PDLI) to enable kaleo to support commercialization of EVZIO(TM)(naloxone hydrochloride injection) and development of key pipeline products. Under the financing, PDL provided $150 million in cash at closing and will receive interest on the principal outstanding. The note is backed by royalty payments on kaleo's first product (Auvi-Q(TM) in the US and Allerject(TM) in Canada) (www.auvi-q.com) and a portion of the net sales on its second product (EVZIO(TM))(www.evzio.com). Once the note is repaid, kaleo will resume receiving 100% of all product royalties and net sales.
PDL BioPharma Completes $150 Million Financing Transaction with kaleo
PR Newswire - Mon Apr 07, 6:00AM CDT
PDL BioPharma, Inc. (NASDAQ: PDLI) today announced that it has acquired $150 million of Notes due 2029 (the Notes) from Accel 300, LLC, a wholly-owned subsidiary of kaleo, Inc. (formerly known as Intelliject, Inc.) (kaleo). The Notes are backed by 100 percent of royalties from kaleo's first approved product, Auvi-Q(TM) (epinephrine auto-injection, USP) (known as Allerject(TM) in Canada) and 10 percent of net sales of kaleo's second proprietary auto-injector based product, EVZIOTM (naloxone hydrochloride injection) (collectively, the Revenue Interests).
Business Plans, Clinical Trial Results, Meetings, Conferences, and Sponsorships - Analyst Notes on Baxter, Halozyme, WellCare, PDL BioPharma, and Lannett
PR Newswire - Tue Apr 01, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Baxter International Inc. (NYSE: BAX), Halozyme Therapeutics, Inc. (NASDAQ: HALO), WellCare Health Plans, Inc. (NYSE: WCG), PDL BioPharma, Inc. (NASDAQ: PDLI), and Lannett Company, Inc. (NYSE: LCI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Buy These Top 3 Buy-Rated Dividend Stocks Today: AB, PDLI, KIM
at The Street - Fri Mar 28, 10:30AM CDT
These 3 dividend stocks are rated a Buy by TheStreet
Depomed A 'Turtle' Gaining In Specialty Pharma Race
at Investor's Business Daily - Tue Mar 25, 4:52PM CDT
Specialty pharmaceutical company Depomed has been around nearly 20 years. But as CEO James Schoeneck says, it has only just begun to realize its potential. Of the four drugs in its product portfolio, three were acquired since 2012. The most recent,...
Momentum Indicators for Health Care Equities -- Research on Arena Pharma, Hemispherx Biopharma, PDL BioPharma and Celgene
PR Newswire - Thu Mar 20, 7:16AM CDT
The trading session on Wednesday, March 19, 2014 ended on a negative note as the S&P 500 finished at 1,860.77, down 0.61%; the NASDAQ Composite closed at 4,307.60, down 0.59%; the Dow Jones Industrial Average finished the session 0.70% lower at 16,222.17. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 686.44, down 0.37%, while the same has advanced 1.72% in the previous three trading sessions. Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Hemispherx Biopharma Inc. (AMEX: HEB), PDL BioPharma Inc. (NASDAQ: PDLI) and Celgene Corp. (NASDAQ: CELG). Free technical research on ARNA, HEB, PDLI and CELG can be downloaded upon signing up at:
5 Reasons to Buy PDL BioPharma Inc
George Budwell, The Motley Fool - Motley Fool - Mon Mar 17, 1:30PM CDT
The wisdom of investing in stocks that pay dividends will never go out of style. For investors in the health care sector, however, dividends are rare, as most health care companies choose to use their cash to invest in their clinical pipelines, which...
Deal Or No Deal: 4 Undervalued Dividend Stocks Under 10 Dollars
at The Street - Fri Mar 14, 4:02PM CDT
a����James Dennin, Kapitall: We built a list of undervalued dividend stocks that are also easy on the wallet. Is the market [...]
PDL BioPharma to Hold Annual Meeting of Stockholders on May 28, 2014
PR Newswire - Thu Mar 13, 3:02PM CDT
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the company will hold its annual meeting of stockholders on Wednesday, May 28, 2014, at 10:00 a.m. Pacific Time for all stockholders of record on April 4, 2014. The meeting will take place at the Hyatt Regency Hotel in Incline Village, Nevada.
Morning Movers in Biotech: Actavis plc, DepoMed, Inc. and Horizon Pharma, Inc.
George Budwell, The Motley Fool - Motley Fool - Thu Mar 13, 8:09AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
PDL BioPharma Completes Regular Quarterly Dividend Payment
PR Newswire - Wed Mar 12, 3:02PM CDT
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the March 12, 2014, regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of March 5, 2014, the record date.
PDL BioPharma Expects Higher Q1 Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 10:10AM CDT
PDL BioPharma announced that it expects to receive revenues of roughly $133 million in the first quarter of 2014.
PDL BioPharma Provides First Quarter 2014 Revenue Guidance of $133 Million
PR Newswire - Tue Mar 11, 3:02PM CDT
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced revenue guidance for the first quarter ending March 31, 2014, of approximately $133 million, as compared with actual revenue of $91.8 million for the first quarter of 2013, an approximate 45 percent increase.
PDL BioPharma Appoints David Gryska to its Board of Directors
PR Newswire - Mon Mar 10, 6:00AM CDT
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced the appointment of David W. Gryska to its board of directors. Mr. Gryska brings more than 30 years of strategic biopharmaceutical and financial leadership experience to PDL and has demonstrated success in implementing successful strategic initiatives, growing companies and executing multi-billion dollar financial transactions.
Buy-Rated Dividend Stocks In The Top 3: PDLI, RCI, CVI
at The Street - Fri Mar 07, 9:30AM CST
These 3 dividend stocks are rated a Buy by TheStreet
PDL BioPharma Misses on Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 8:20AM CST
PDL BioPharma posted fourth-quarter 2013 earnings of 39 cents per share, below the Zacks Consensus Estimate of 41 cents.
PDL BioPharma Announces Conversion Rate Adjustments for Convertible Notes
PR Newswire - Tue Mar 04, 3:02PM CST
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the adjusted conversion rate for the:
PDL BioPharma's Q4 Profit Jumps 24% on Higher Royalty Revenue
Sean Williams, The Motley Fool - Motley Fool - Mon Mar 03, 5:04PM CST
The biopharmaceutical sector's most lucrative dividend-paying company, PDL BioPharma , reported its fourth-quarter earnings results after the bell this evening. Based on early indications, it would appear that everything seems to be headed in the...
Coverage of Biotech Equities -- Research on Arena Pharma, Celgene, PDL BioPharma, and Hemispherx Biopharma
PR Newswire - Tue Apr 08, 12:20PM CDT
On Monday, April 07, 2014, the NASDAQ Composite ended at 4,079.75, down 1.16%, the Dow Jones Industrial Average finished the session 1.02% lower at 16,245.87, and the S&P 500 closed at 1,845.04, down 1.08%. The losses were broad based as nine out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index finished the day 1.06% lower at 664.68, while the same has gained 3.19% in the previous three months. Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Celgene Corp. (NASDAQ: CELG), PDL BioPharma Inc. (NASDAQ: PDLI) and Hemispherx Biopharma Inc. (NYSE MKT: HEB). Free technical research on ARNA, CELG, PDLI and HEB can be downloaded upon signing up at:
Kaleo awarded USD150m debt financing in support of EVZIO's commercial activities
M2 - Tue Apr 08, 7:07AM CDT
Pharmaceutical company Kaleo reported on Monday the execution of a USD150m debt facility with PDL BioPharma (NasdaqGS
DLI). kaleo announces $150 million debt financing to support commercialization of EVZIO(TM)
PR Newswire - Mon Apr 07, 6:51AM CDT
Kaleo (formerly Intelliject) today announced that it has entered into a $150 million debt facility with PDL BioPharma (NASDAQ: PDLI) to enable kaleo to support commercialization of EVZIO(TM)(naloxone hydrochloride injection) and development of key pipeline products. Under the financing, PDL provided $150 million in cash at closing and will receive interest on the principal outstanding. The note is backed by royalty payments on kaleo's first product (Auvi-Q(TM) in the US and Allerject(TM) in Canada) (www.auvi-q.com) and a portion of the net sales on its second product (EVZIO(TM))(www.evzio.com). Once the note is repaid, kaleo will resume receiving 100% of all product royalties and net sales.
PDL BioPharma Completes $150 Million Financing Transaction with kaleo
PR Newswire - Mon Apr 07, 6:00AM CDT
PDL BioPharma, Inc. (NASDAQ: PDLI) today announced that it has acquired $150 million of Notes due 2029 (the Notes) from Accel 300, LLC, a wholly-owned subsidiary of kaleo, Inc. (formerly known as Intelliject, Inc.) (kaleo). The Notes are backed by 100 percent of royalties from kaleo's first approved product, Auvi-Q(TM) (epinephrine auto-injection, USP) (known as Allerject(TM) in Canada) and 10 percent of net sales of kaleo's second proprietary auto-injector based product, EVZIOTM (naloxone hydrochloride injection) (collectively, the Revenue Interests).
Business Plans, Clinical Trial Results, Meetings, Conferences, and Sponsorships - Analyst Notes on Baxter, Halozyme, WellCare, PDL BioPharma, and Lannett
PR Newswire - Tue Apr 01, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Baxter International Inc. (NYSE: BAX), Halozyme Therapeutics, Inc. (NASDAQ: HALO), WellCare Health Plans, Inc. (NYSE: WCG), PDL BioPharma, Inc. (NASDAQ: PDLI), and Lannett Company, Inc. (NYSE: LCI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Buy These Top 3 Buy-Rated Dividend Stocks Today: AB, PDLI, KIM
at The Street - Fri Mar 28, 10:30AM CDT
These 3 dividend stocks are rated a Buy by TheStreet
Depomed A 'Turtle' Gaining In Specialty Pharma Race
at Investor's Business Daily - Tue Mar 25, 4:52PM CDT
Specialty pharmaceutical company Depomed has been around nearly 20 years. But as CEO James Schoeneck says, it has only just begun to realize its potential. Of the four drugs in its product portfolio, three were acquired since 2012. The most recent,...
Momentum Indicators for Health Care Equities -- Research on Arena Pharma, Hemispherx Biopharma, PDL BioPharma and Celgene
PR Newswire - Thu Mar 20, 7:16AM CDT
The trading session on Wednesday, March 19, 2014 ended on a negative note as the S&P 500 finished at 1,860.77, down 0.61%; the NASDAQ Composite closed at 4,307.60, down 0.59%; the Dow Jones Industrial Average finished the session 0.70% lower at 16,222.17. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 686.44, down 0.37%, while the same has advanced 1.72% in the previous three trading sessions. Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Hemispherx Biopharma Inc. (AMEX: HEB), PDL BioPharma Inc. (NASDAQ: PDLI) and Celgene Corp. (NASDAQ: CELG). Free technical research on ARNA, HEB, PDLI and CELG can be downloaded upon signing up at:
5 Reasons to Buy PDL BioPharma Inc
George Budwell, The Motley Fool - Motley Fool - Mon Mar 17, 1:30PM CDT
The wisdom of investing in stocks that pay dividends will never go out of style. For investors in the health care sector, however, dividends are rare, as most health care companies choose to use their cash to invest in their clinical pipelines, which...
Deal Or No Deal: 4 Undervalued Dividend Stocks Under 10 Dollars
at The Street - Fri Mar 14, 4:02PM CDT
a����James Dennin, Kapitall: We built a list of undervalued dividend stocks that are also easy on the wallet. Is the market [...]
PDL BioPharma to Hold Annual Meeting of Stockholders on May 28, 2014
PR Newswire - Thu Mar 13, 3:02PM CDT
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the company will hold its annual meeting of stockholders on Wednesday, May 28, 2014, at 10:00 a.m. Pacific Time for all stockholders of record on April 4, 2014. The meeting will take place at the Hyatt Regency Hotel in Incline Village, Nevada.
Morning Movers in Biotech: Actavis plc, DepoMed, Inc. and Horizon Pharma, Inc.
George Budwell, The Motley Fool - Motley Fool - Thu Mar 13, 8:09AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
PDL BioPharma Completes Regular Quarterly Dividend Payment
PR Newswire - Wed Mar 12, 3:02PM CDT
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the March 12, 2014, regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of March 5, 2014, the record date.
PDL BioPharma Expects Higher Q1 Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 10:10AM CDT
PDL BioPharma announced that it expects to receive revenues of roughly $133 million in the first quarter of 2014.
PDL BioPharma Provides First Quarter 2014 Revenue Guidance of $133 Million
PR Newswire - Tue Mar 11, 3:02PM CDT
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced revenue guidance for the first quarter ending March 31, 2014, of approximately $133 million, as compared with actual revenue of $91.8 million for the first quarter of 2013, an approximate 45 percent increase.
PDL BioPharma Appoints David Gryska to its Board of Directors
PR Newswire - Mon Mar 10, 6:00AM CDT
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced the appointment of David W. Gryska to its board of directors. Mr. Gryska brings more than 30 years of strategic biopharmaceutical and financial leadership experience to PDL and has demonstrated success in implementing successful strategic initiatives, growing companies and executing multi-billion dollar financial transactions.
Buy-Rated Dividend Stocks In The Top 3: PDLI, RCI, CVI
at The Street - Fri Mar 07, 9:30AM CST
These 3 dividend stocks are rated a Buy by TheStreet
PDL BioPharma Misses on Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 8:20AM CST
PDL BioPharma posted fourth-quarter 2013 earnings of 39 cents per share, below the Zacks Consensus Estimate of 41 cents.
PDL BioPharma Announces Conversion Rate Adjustments for Convertible Notes
PR Newswire - Tue Mar 04, 3:02PM CST
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the adjusted conversion rate for the:
PDL BioPharma's Q4 Profit Jumps 24% on Higher Royalty Revenue
Sean Williams, The Motley Fool - Motley Fool - Mon Mar 03, 5:04PM CST
The biopharmaceutical sector's most lucrative dividend-paying company, PDL BioPharma , reported its fourth-quarter earnings results after the bell this evening. Based on early indications, it would appear that everything seems to be headed in the...
